
Absci Corp (ABSI) Stock Forecast & Price Target
Absci Corp (ABSI) Analyst Ratings
Bulls say
Absci Corp is positioned favorably due to its promising clinical activity with ABS-101, which could enhance the probability of success in ulcerative colitis (UC) and Crohn's disease (CD) to 15%. Strong initial results from ABS-101 could not only validate Absci's innovative platform but also attract interest from large pharmaceutical companies, highlighting the potential for significant partnerships. Additionally, the expansion of collaborations, such as with Almirall, demonstrates Absci's ability to deliver results in challenging therapeutic areas, reinforcing its growth trajectory in the biologics market.
Bears say
The analysis identifies a negative outlook on Absci Corp's stock primarily due to increased dilution resulting from a recent financing round, which has adversely affected its valuation metrics. Additionally, there are concerns regarding the standard of care in the endo sector, particularly for non-hormonal treatment options, which may limit market opportunities and investor confidence. Overall, these factors contribute to a weakened perception of the company's financial stability and future growth prospects.
This aggregate rating is based on analysts' research of Absci Corp and is not a guaranteed prediction by Public.com or investment advice.
Absci Corp (ABSI) Analyst Forecast & Price Prediction
Start investing in Absci Corp (ABSI)
Order type
Buy in
Order amount
Est. shares
0 shares